Josh Brown of Ritholtz Wealth Management has increased his position in Pfizer Inc (NYSE:PFE) by 50%, citing the stock's current trading at an 11-year low and a 6.5% dividend yield as a prime investment opportunity. Despite the lack of near-term catalysts and a 60% drawdown due to slowing vaccine demand, Brown views Pfizer's acquisition of Seagen as a potential turning point, especially for oncology drugs. He plans to hold Pfizer shares for the long term, believing in the company's ability to rebuild and reorient.